查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1458429

印度醫用大麻市場評估：依物種、衍生物、給藥途徑、形式、治療用途、最終用戶和地區劃分的機會和預測（2017 財年-2031 財年）

India Medical Cannabis Market Assessment, By Species, By Derivatives, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, FY2017-FY2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 128 Pages | 商品交期: 3-5個工作天內

價格

印度醫用大麻市場規模預計將從 2023 年的 1,536 萬美元成長到 2031 年的 4,715 萬美元，2024-2031 年的複合年增長率為 15.05%。

印度醫用大麻市場的成長是由焦慮和憂鬱症的盛行率不斷上升、醫療產業中醫用大麻的使用不斷增加以及領先公司研究醫用大麻在各種醫療條件下的潛在益處所推動的。，包括公司研發活動的增加。此外，人們對安全使用醫用大麻治療癲癇和疼痛等健康狀況的接受度不斷提高，也促進了印度市場的成長。

印度醫用大麻市場由於其治療焦慮、憂鬱、慢性疼痛和癲癇的潛力而正在經歷顯著增長。醫用大麻衍生物，如大麻二酚，以多種形式出售，包括 CBD 油、膠囊和外用乳膏，可以緩解疼痛和具有治療作用。因此，一些公共機構和私人公司越來越多地投資於研發活動，以加強這些產品在治療其他疾病方面的用途。這些因素正在推動印度醫用大麻市場的成長。

有利的監管框架、新的市場進入、併購、夥伴關係、公司間分銷協議等合作活動的增加以及主要參與者持續推出的創新產品也將進一步推動印度醫用大麻市場的發展。2023 年 2 月，總部位於孟買的工業大麻和醫用大麻公司 Bombay Hemp Company (BOHECO) 推出了多項醫療創新產品，包括緩解關節疼痛的 GLIDE+ 和改善濕疹的 PRISTINE 等。我們也透過將這些產品出口到海外來擴大我們的銷售管道。如此頻繁的產品推出預計也將推動印度醫用大麻市場的發展。

憂鬱症患者增加：

由於印度焦慮和憂鬱等心理健康問題日益普遍，對醫用大麻的需求大幅增加。心理健康障礙變得越來越普遍，影響著不同年齡層和地區的大量個體。根據Sapien Labs Centre for the Human Brain and Mind at Krea University編製並發佈的《Mental State of India Rapid Report 2023》，2020年，有網路存取的印度人口中，有46%面臨心理健康問題，這一比例還將繼續上升到 2023 年將達到 50%。這說明印度人的心理健康狀況正在逐年惡化。失業、過度使用智慧型手機和不健康的生活方式是導致人們心理健康狀況不佳的主要原因。醫用大麻產品可能被證明是解決這一日益嚴重的心理健康狀況不佳問題的有效解決方案。

該報告調查了印度的醫用大麻市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構、影響市場增長的因素分析以及案例研究。簡介等

目錄

第一章研究方法論

第二章 專案範圍與定義

第 3 章執行摘要

第四章 印度醫用大麻市場展望

  • 市場規模/預測
  • 類型
    • 秈稻
    • 苜蓿
    • 雜交種
  • 依衍生產品分類
    • 大麻二酚 (CBD)
    • 四氫大麻酚 (THC)
    • 其他
  • 依給藥途徑
    • 口服
    • 當地的
    • 其他
  • 依形式
    • Oil
    • 膠囊
    • 酊劑
  • 依治療用途
    • 癌症
    • 偏頭痛
    • 癲癇
    • 焦慮/憂鬱
    • 其他
  • 依最終用戶
    • 製藥業
    • 研發中心
    • 其他
  • 依地區
    • 北方
    • 南部
    • 東
    • 西部/中部地區
  • 市佔率：依公司劃分，2023 財年

第 5 章 市場測繪，2023 年

  • 類型
  • 依衍生產品分類
  • 依給藥途徑
  • 依形式
  • 依治療用途
  • 依最終用戶
  • 依地區

第六章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第七章市場動態

  • 生長促進因子
  • 生長抑制因素（問題/限制）

第八章 監理框架與創新

  • 臨床試驗
  • 專利情況
  • 監管審批
  • 創新/新興技術

第九節 主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析
  • 併購/合資（如適用）
  • SWOT分析（5家參與企業）
  • 專利分析（如果適用）

第10章價格分析

第11章案例研究

第十二章 主要公司展望

  • Hemp Organics Pvt Ltd (India Hemp Organics)
  • Ananta Hempworks Solutions Pvt. Ltd.
  • Bombay Hemp Company Private Limited (BOHECO)
  • HempCann Solutions Pvt. Ltd. (Vedi)
  • Indian Industrial Hemp Association
  • Hemp Horizons Private Limited
  • VeganMall
  • CannazoIndia
  • Cannarie (Varka Labs Private Limited)
  • Cannarma Private Limited

第十三章 戰略建議

第14章關於我們公司/免責聲明

Product Code: MX10029

India medical cannabis market is projected to witness a CAGR of 15.05% during the forecast period FY2024-FY2031, growing from USD 15.36 million in FY2023 to USD 47.15 million in FY2031. India medical cannabis market growth is driven by various factors, such as increasing prevalence of anxiety and depression, increased applications of medical cannabis in the healthcare industry, and increase in research and development (R&D) activities by leading players to study the potential benefits of medical cannabis in different medical conditions. Growing acceptance among the people regarding the safe usage of medical cannabis for health conditions, such as epilepsy and pain management, is also leading to the growth of this market in India.

The India medical cannabis market is undergoing significant growth due to its potential in treating anxiety, depression, chronic pain, and epilepsy. Medical cannabis derivatives, such as cannabidiol, is available in various forms, including CBD oils, capsules, and topical creams, that provide pain relief and therapeutical advantages. Due to which, several public and private organizations are increasingly investing in R&D activities to enhance use of these products to treat other medical conditions. These factors are driving the growth of the India medical cannabis market.

Favorable regulatory framework, new entrances in the market, increased collaboration activities, such as mergers and acquisitions, partnerships, and distribution agreements between the companies, along with consistent innovative product launches by key market players, further propels the India medical cannabis market. For Instance, in February 2023, Bombay Hemp Company (BOHECO), which is a Mumbai-based industrial hemp and medical cannabis company, launched several innovative medical cannabis-based products such as GLIDE+ for joint pain relief and PRISTINE for improvement in eczema. Along with this, the company is also expanding its market reach by exporting these products to several international destinations. These frequent product launches are expected to flourish the India medical cannabis market.

Increasing Prevalence of Depression

The demand for medical cannabis has significantly increased due to the growing prevalence of mental health issues like anxiety and depression among the Indian population. Mental health conditions are becoming increasingly common, affecting a substantial number of individuals across various age groups and geographical locations. For instance, according to Mental State of India Rapid Report 2023, conducted and published by the "Sapien Labs Centre for the Human Brain and Mind at Krea University", 46% of the internet-enabled Indian population were dealing with poor mental health in the year 2020 and this percentage has increased to 50% in the year 2023. This indicates that the mental health of the Indian population is gradually affecting over the years. Unemployment, excessive use of smart-phones, and unhealthy lifestyles are the main drivers for this increasing poor mental health of the population. Medical cannabis-based products can prove to be an effective solution for this growing poor mental health issue. Numerous research studies have demonstrated medical cannabis effectiveness in treating depression and anxiety, resulting in significant enhancements in people's health conditions. As a result, many companies are integrating medical cannabis in their product portfolio for a variety of health conditions, such as pain, migraines, cancer, and epilepsy, thereby driving the growth of the Indian medical cannabis market.

Favorable Regulatory Framework

India medical cannabis market size is influenced by the implementation of favorably regulatory framework by the Government of India (GoI). These considerations within the regulatory bodies to approve novel medical cannabis-based products in the healthcare sector can be attributed to the growing demand for medical cannabis, increasing R&D activities, and growing awareness regarding the tremendous potential of medical cannabis in treating several health conditions. For instance, in May 2023, Biophore India Pharmaceuticals announced that its subsidiary, "Zenara Pharma" has received approval from the Central Drugs Standard Control Organization to manufacture medical cannabis-based products in India. This approval has been granted for treating seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. These favorable regulatory policies are expected to accelerate the growth of the India medical cannabis market.

Increased Demand for Cannabidiol

Among the derivative segment, cannabidiol (CBD) segment holds significant market share in the India medical cannabis market. In comparison with THC, CBD-based products are used in vast medical applications such as pain management, epilepsy, and cancer. CBD-based products are legalized and are easy to access, which makes them highly popular among the manufacturers and consumers. Additionally, several leading players are launching CBD-based products in their portfolio for various medical purposes, which is boosting the India medical cannabis market demand. For instance, in April 2023, Cansaa, which is Chennai's first medical cannabis clinic, has been opened to provide treatment by using combination of ayurveda and functional medicines such as CBD oils, tinctures, creams, and acupuncture. As the awareness regarding the potential benefits of CBD in healthcare industry is increasing, more healthcare settings are expected to adopt CBD-based products in their services. These factors are escalating growth in the India medical cannabis market.

Increased Demand of Medical Cannabis in Epilepsy

Among the therapeutic application segment, medical cannabis is widely used for the treatment of epilepsy and thus, this segment holds a significant market share in the overall India medical cannabis market. Several studies have shown that medical cannabis exuberates promising effects in the treatment of epilepsy, especially in certain epileptic conditions. For instance, an article published in the "Behavioral Neurology Journal" in the year 2023, states that medical cannabis has potential therapeutic applications in treating neurological conditions such as epilepsy, multiple sclerosis, Alzheimer's, and Parkinson's disease. Due to this, regulatory bodies, such as the European Medicines Agency and the U.S. Food and Drug Administration, have approved medical cannabis-based products, such as CBD oil, for use in certain epilepsy treatments. Moreover, frequent innovative and advanced product launches by key market players in this industry, to provide quality treatment, further accelerates growth of this segment in India.

Future Market Scenario (FY2024 - FY2031F)

The India medical cannabis market is expected to grow in the future, due to multiple factors. Primarily, the increasing prevalence of anxiety and depression among the population has enhanced company's focus in developing medical cannabis-based products that can help with relieving mental stress among the users. Increased acceptance among the healthcare providers regarding the capabilities of medical cannabis in the treatment of anxiety, depression, epilepsy has enabled the pharmaceutical companies to increase investments in this market. There has been a surge in research and development activities in this market to further explore the potential benefits of medical cannabis in patient's treatments. Collaborative ventures among the companies, improved and supportive regulatory framework and new entrances have spurred growth in the India medical cannabis market. For Instance, Cannarma, which is a growing start-up established in the year 2022, that manufactures a wide range of ayurvedic products, such as CBD oil, hemp seed oil, and medicinal cannabis announced its plan to establish around 10,000 medical stores, clinics, and hospitals throughout India, expanding its domestic market. These potential new entrants are further leading to the growth in the India medical cannabis market.

Key Players Landscape and Outlook

Numerous pharmaceutical companies are consistently forming strategic partnerships and distribution agreements, which plays a crucial role in driving the expansion of the Indian medical cannabis market. These partnerships allow firms to gain valuable insights into the market, leverage each other's resources, markets, and technologies, and invest in research and development activities to bring advancements to the market. Distribution agreements enable companies to expand their market presence at a national level in India. These collaborative initiatives foster innovation, expertise in product development, and contribute to the sustained and robust growth of the Indian market. For instance, in July 2023, Carer, which is a Bengaluru-based startup, announced its collaboration partnership with Wholeleaf, which is a licensed medical cannabis company. This strategic collaboration aims to improve the quality of life of cancer patients by providing medical cannabis-based products that can ease pain and improve physical and mental well-being of the patients. These consistent collaboration activities further assist in the India medical cannabis market expansion.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.India Medical Cannabis Market Outlook, FY2017-FY2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Species
    • 4.2.1.Indica
    • 4.2.2.Sativa
    • 4.2.3.Hybrid
  • 4.3.By Derivatives
    • 4.3.1.Cannabidiol (CBD)
    • 4.3.2.Tetrahydrocannabinol (THC)
    • 4.3.3.Others
  • 4.4.By Route of Administration
    • 4.4.1.Oral
    • 4.4.2.Topical
    • 4.4.3.Others
  • 4.5.By Form
    • 4.5.1.Oils
    • 4.5.2.Capsules
    • 4.5.3.Tinctures
  • 4.6.By Therapeutic Application
    • 4.6.1.Cancer
    • 4.6.2.Migraine
    • 4.6.3.Epilepsy
    • 4.6.4.Anxiety and Depression
    • 4.6.5.Others
  • 4.7.By End-user
    • 4.7.1.Pharmaceutical Industry
    • 4.7.2.Research and Development Centers
    • 4.7.3.Others
  • 4.8.By Region
    • 4.8.1.North
    • 4.8.2.South
    • 4.8.3.East
    • 4.8.4.West and Central
  • 4.9.By Company Market Share (%), FY2023

5.Market Mapping, FY2023

  • 5.1.By Species
  • 5.2.By Derivatives
  • 5.3.By Route of Administration
  • 5.4.By Form
  • 5.5.By Therapeutic Application
  • 5.6.By End-user
  • 5.7.By Region

6.Macro Environment and Industry Structure

  • 6.1.Demand Supply Analysis
  • 6.2.Import Export Analysis
  • 6.3.Value Chain Analysis
  • 6.4.PESTEL Analysis
    • 6.4.1.Political Factors
    • 6.4.2.Economic System
    • 6.4.3.Social Implications
    • 6.4.4.Technological Advancements
    • 6.4.5.Environmental Impacts
    • 6.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 6.5.Porter's Five Forces Analysis
    • 6.5.1.Supplier Power
    • 6.5.2.Buyer Power
    • 6.5.3.Substitution Threat
    • 6.5.4.Threat from New Entrant
    • 6.5.5.Competitive Rivalry

7.Market Dynamics

  • 7.1.Growth Drivers
  • 7.2.Growth Inhibitors (Challenges and Restraints)

8.Regulatory Framework and Innovation

  • 8.1.Clinical Trials
  • 8.2.Patent Landscape
  • 8.3.Regulatory Approvals
  • 8.4.Innovations/Emerging Technologies

9.Key Players Landscape

  • 9.1.Competition Matrix of Top Five Market Leaders
  • 9.2.Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
  • 9.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 9.4.SWOT Analysis (For Five Market Players)
  • 9.5.Patent Analysis (If Applicable)

10.Pricing Analysis

11.Case Studies

12.Key Players Outlook

  • 12.1.Hemp Organics Pvt Ltd (India Hemp Organics)
    • 12.1.1.Company Details
    • 12.1.2.Key Management Personnel
    • 12.1.3.Products & Services
    • 12.1.4.Financials (As reported)
    • 12.1.5.Key Market Focus & Geographical Presence
    • 12.1.6.Recent Developments
  • 12.2.Ananta Hempworks Solutions Pvt. Ltd.
  • 12.3.Bombay Hemp Company Private Limited (BOHECO)
  • 12.4.HempCann Solutions Pvt. Ltd. (Vedi)
  • 12.5.Indian Industrial Hemp Association
  • 12.6.Hemp Horizons Private Limited
  • 12.7.VeganMall
  • 12.8.CannazoIndia
  • 12.9.Cannarie (Varka Labs Private Limited)
  • 12.10. Cannarma Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13.Strategic Recommendations

14.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.India Medical Cannabis Market, By Value, In USD Million, FY2017-FY2031F
  • Figure 2.India Medical Cannabis Market, By Volume, In Million Units, FY2017-FY2031F
  • Figure 3.India Medical Cannabis Market Share (%), By Species, FY2017-FY2031F
  • Figure 4.India Medical Cannabis Market Share (%), By Derivatives, FY2017-FY2031F
  • Figure 5.India Medical Cannabis Market Share (%), By Route of Administration, FY2017-FY2031F
  • Figure 6.India Medical Cannabis Market Share (%), By Form, FY2017-FY2031F
  • Figure 7.India Medical Cannabis Market Share (%), By Therapeutical Application, FY2017-FY2031F
  • Figure 8.India Medical Cannabis Market Share (%), By End-user, FY2017-FY2031F
  • Figure 9.India Medical Cannabis Market Share (%), By Region, FY2017-FY2031F
  • Figure 10.By Species Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 11.By Derivatives Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 12.By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 13.By Form Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 14.By Therapeutical Application Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 15.By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 16.By Region Map-Market Size (USD Million) & Growth Rate (%), FY2023